Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 1(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05965687Phase 3Completed

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)

Role: collaborator

NCT07171320Not ApplicableRecruiting

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia

Role: collaborator

NCT04144868Phase 2Completed

Normobaric Hyperoxia for Intracerebral Hemorrhage

Role: collaborator

NCT04681651Phase 2Completed

Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)

Role: collaborator

NCT04270461Phase 1Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Role: lead

All 5 trials loaded